No plans to postpone the launch of the AstraZeneca vaccine



[ad_1]

BAGAN WILL BEThe government has no plans to postpone the administration of the AstraZeneca Covid-19 vaccine, despite reports of its side effects in recipients abroad, said Deputy Health Minister Datuk Dr. Noor Azmi Ghazali.

He said the reported side effects were treatable allergies, plus there has been no evidence that the vaccine causes adverse effects or death.

“If side effects occur, the doctors at the vaccination centers will provide immediate treatment and, until now, recipients of other types of vaccines have also experienced side effects and were treated appropriately.

“Don’t worry because we have drugs to treat allergies like muscle pain, fever or itching,” he said at a press conference at the Back to School Haircutting Program for schools in the Bagan Serai parliamentary constituency in Pusat GiatMara Bagan. It will be here today.

Yesterday, the Director General of Health, Tan Sri Dr. Noor Hisham Abdullah, said that the Drug Control Authority (DCA) agreed to approve the conditional registration of AstraZeneca’s injectable solution of the Covid-19 vaccine, which will be supplied through from Covax facilities by South Korean manufacturer SK Bioscience Co Limited, for use during an emergency.

In elaborating, Dr. Noor Azmi, who is also a member of the Bagan Serai parliament, said that the AstraZeneca vaccine, produced from a viral vector by placing a weak virus with protein, was expected to stimulate the human body in a similar way to other vaccines, will arrive in Malaysia in May. .

Previously, 80 primary and secondary school students in the Bagan Serai parliamentary constituency received free haircut services from GiatMara graduates before the schools reopened next Monday.

Dr. Noor Azmi said that in addition to the annual program, the less fortunate students also received payment of the Parent Teacher Association fee and assistance with school supplies to reduce their burden due to the spread of the Covid-19 pandemic. – Named



[ad_2]